<DOC>
	<DOCNO>NCT02587260</DOCNO>
	<brief_summary>The purpose randomize , cross-over study , ascertain ticagrelor , prasugrel clopidogrel , associate improved endothelial function assess peripheral arterial tonometry marker endothelial function measurement post-ACS patient .</brief_summary>
	<brief_title>Hunting Off-Target Properties Ticagrelor Endothelial Function Humans ( HI-TECH )</brief_title>
	<detailed_description>Extensive literature document endothelial dysfunction associate almost every condition predispose atherosclerosis cardiovascular disease . Hence , endothelial dysfunction significantly associate burden cardiovascular risk consider barometer total risk burden . Importantly , microvascular dysfunction show increase risk future cardiovascular event . This study aim clarify ticagrelor , prasugrel clopidogrel associate improved reactive hyperemia index ( RHI ) circulating level specific biomarkers endothelial function , treatment steady state . Ticagrelor previously demonstrate increase adenosine level inhibit adenosine reuptake red blood cell , inhibit equilibrative nucleoside transporter ( ENT ) -1 . Furthermore , ticagrelor induce adenosine triphosphate ( ATP ) release human red blood cell . Interestingly , ticagrelor , clopidogrel prasugrel recently show associate improved endothelial function evaluate peripheral arterial tonometry forearm ischemia . Post-ACS patient ( experienced acute coronary syndrome thereby start therapy oral P2Y12 inhibitor least 30 day ) consecutively screen possible inclusion . Patients randomise receive sequential manner three oral P2Y12 blocker ( i.e . ) ticagrelor , prasugrel clopidogrel least 30 day , accord balance cross-over study design include sequence : Seq\ Per P.I P.II P.III S.I T P C S.II T C P S.III P T C S.IV P C T S.V C T P S.VI C P T During three month study period therapy P2Y12 inhibitor switch randomization sequence scheme . When start , drug give correspond load dose 600 mg clopidogrel continue 75 mg/day , 180 mg ticagrelor continue 90 mg b.i.d . 60 mg prasugrel continue 10 mg/day ( 5 mg/day patient ≥75 year weigh ≤ 60 kg ) . The main measurement , include reactive hypermedia index , PRU , aspirin reaction unit , circulate marker endothelial function perform baseline , P2Y12-inhibitor load dose , P2Y12-inhibitor maintenance dose . During visit , blood pressure measure contralateral arm examination . The EndoPAT probe place index finger . If index finger miss deform , another finger use , use finger hand . Baseline registration conduct 5 min . The test arm occlude 5 min , use standard blood pressure cuff place upper arm . Subsequently , cuff deflate registration continue 5 minute . After EndoPAT , blood drawn collect serum plasma biomarkers assessment [ Asymmetrical dimethylarginine ( ADMA ) , adenosine plasma concentration , von willebrand factor antigen , endothelin-1 , C-reactive protein , soluble fms-like tyrosine kinase-1 ( sFLT-1 ) , intercellular cell adhesion molecule-1 ( ICAM-1 ) , vascular cell adhesion molecule-1 ( VCAM-1 ) , prothrombin fragment 1+2 , fibrinopeptide A , thrombin-antithrombin complex ( TAT ) ] . To assess relationship residual platelet reactivity percent inhibition effect P2Y12 oral blocker endothelial function , platelet function test also carry acutely treatment steady state mean Verifynow system use P2Y12 aspirin assay . Based previous finding , set mean RHI 1.8 within subject SD 0.31 . Hence , 36 patient complete sequence ( i.e . 6 pt/sequence ) provide 90 % power detect 10 % RHI relative change ticagrelor group two-sided alpha level 5 % . To account drop outs well incomplete data assessment time point , final sample size 50 patient recruit . Patients provide regular drug prescription ( standard care medication ) . At follow-up investigator collect information adherence study drug register charge number prescribe P2Y12 . Allocation study treatment perform via web-based interactive randomization system , base computer-generated random sequence random block size stratify accord type P2Y12 inhibitor ( ticagrelor v prasugrel v clopidogrel ) well presence diabetes mellitus . Adverse event define undesirable experience occur subject study , whether consider related study . All adverse event report spontaneously subject observe investigator staff record . Serious adverse event study consider extremely rare .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients older 18 year . Patients experience Acute Coronary Syndrome ( include STEMI NSTEMI ) least 30 day . Patients ongoing treatment least 30 day dual antiplatelet therapy consist aspirin , dose 75160 mg daily one commercially available P2Y12 oral inhibitor , include ticagrelor , clopidogrel prasugrel . Patients remain free bleeding ( define BARC type 2 great ) ischemic recurrence . Signed informed consent All inclusion criterion require . Administration fibrinolytics glycoprotein IIb/IIIa inhibitor previous 30 day . Major surgery within 30 day plan surgical percutaneous intervention . Active bleed previous clinical relevant bleed stroke last 6 month . Previous transient ischemic attack intracranial bleeding . Thrombocytopenia . Oral anticoagulant therapy . Vasculitis know immunological disorder . Severe hepatic failure . Uncontrolled hypertension ( systolic diastolic arterial pressure &gt; 180 mmHg 120 , respectively , despite medical therapy ) . Known intolerance aspirin clopidogrel prasugrel ticagrelor . Limited life expectancy , e.g . neoplasm , others . Inability obtain informed consent . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>P2Y12 inhibitor</keyword>
	<keyword>Acute Coronary Syndrome ( ACS )</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Adenosine measurement human subject</keyword>
	<keyword>Endopath</keyword>
</DOC>